Bruton tyrosine kinase (BTK) ibrutinib was the first in-class agent approved in the United States and European Union for the treatment of relapsed/refractory CLL following the successful results of the RESONATE randomised phase III trial showing significantly longer PFS and OS of ibrutinib vs. ofatumumab [56]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.